MHRA authorises uses of Casgevy as a potential cure for sickle cell disease and beta thalassemia
Britain’s drugs regulator has approved a groundbreaking treatment for two painful and debilitating lifelong blood disorders, which works by “editing” the gene that causes them.
The Medicines and Healthcare products Regulatory Agency (MHRA) has given the green light for Casgevy to be used to treat sickle cell disease and beta thalassemia.
More Stories
Starwatch: Boötes, the herdsman ploughing the heavens
AI can be more persuasive than humans in debates, scientists find
Bankrupt DNA testing firm 23andMe to be purchased for $256m